Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Recruiting
Phase 2
Interventional Study
Acute Lymphobkastic Leukemia
Acute Lymphoblastic Leukaemia Recurrent
Philadelphia Chromosome Negative ALL
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 16 – 45
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 12 (estimated)
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries. With such poor 5-year overall survival rates of 10%, the investigators need strategies that surpass the complete response rate achieved in this setting, which does not exceed 60% effectiveness with different regimens, and to eventually transfer patients to…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* B-cell or T-cell acute lymphoblastic leukemia.
* Philadelphia chromosome negative
* Relapsed disease after any line of treatment, defined as detection of disease activity at any time after remission
* Refractory disease after first-line treatment, defined as: more than 5% blas…
Contacts